Reduction of Artificial Tears and Use of Adjunctive Dry Eye Therapies After Lifitegrast Treatment: Evidence from Clinical and Real-World Studies.

Purpose: To assess the frequency of patients reducing the use of artificial tears (ATs) among patients with dry eye disease (DED) following lifitegrast treatment. Patients and
Methods: Two independent analyses were performed using the data from the 1-year, randomized, multicenter, Phase 3 SONATA trial and a noninterventional, real-world evidence (RWE) study conducted in patients with DED who were treated with lifitegrast in the United States and Canada. In SONATA, patients who had used ATs in the lifitegrast and placebo groups were included. The RWE study reviewed patients' electronic medical records, prescribing patterns, and practices of physicians throughout the survey. These data were then used to compare the proportion of patients using ATs in the 6-month pre-index period versus the 12-month post-index period.
Results: Of 293 patients (lifitegrast, n=195; placebo, n=98) from SONATA, 107 (lifitegrast, n=64; placebo, n=43) used ATs during the on-therapy period while 186 (lifitegrast, n=131; placebo, n=55) did not. Of those not using ATs, the proportion of patients in the lifitegrast group at any time was higher (~67% [n=131]) versus placebo (~56% [n=55]); this was the case at all study time-points (Days 90, 180, 270, and 360). The RWE study included 600 patient charts (US, n=550; Canada, n=50); 75.5% (n=453) reported AT use. There was ~40% decrease in the proportion of patients using ATs as adjunct DED therapy to lifitegrast in the post-index period (n=273) versus those in the pre-index period (n=453).
Conclusion: The findings show that the reliance on AT use can be gradually reduced with lifitegrast treatment, eventually leading to a reduction in disease burden.

Introduction

Dry eye disease (DED) is a multifactorial, inflammatory disease of the ocular surface characterized by symptoms of dryness, irritation, or burning; these can damage the cornea and conjunctiva in the long term.1,2 Tear film instability, hyperosmolarity, and inflammation contribute to the physio-pathological process and trigger a loss of tear film homeostasis and a vicious cycle in DED.2 DED can substantially affect vision and quality of life (QoL), including activities such as reading, writing, social activities, or workplace productivity.3,4

Over the counter (OTC) artificial tears (ATs) are considered the first-line treatment in patients with DED.2,5,6 Due to the easy accessibility and immediate symptomatic relief provided by ATs, most patients initially self-manage their DED.6,7 As their symptoms become more pronounced, patients become more reliant on use of ATs. Even though OTC ATs can provide temporary symptomatic relief, they do not address the underlying disease mechanisms and provide negligible impact on disease intervention.8,9 A Cochrane Systematic Review of 43 randomized controlled trials found that most OTC ATs provide only symptomatic relief.5 In addition, many OTC ATs contain preservatives that may damage the ocular surface associated with allergic, toxic, or inflammatory reactions in the long term if used frequently.10,11

Disrupting the vicious cycle of inflammation on the ocular surface is hypothesized to be important in managing DED and preventing its progression. Besides ATs, current treatments include topical ophthalmic corticosteroids, which have been shown to rapidly improve both signs and symptoms in patients with DED, together with immunomodulators and non-steroidal anti-inflammatory drugs.11,12 However, frequent use of corticosteroids has safety concerns.11,12 Immunomodulators such as cyclosporine A (CsA) 0.05% eye drops/emulsions have been available in certain markets for many years and have resulted in a reduction of cytokines and inflammatory cells on the ocular surface; however, their slow onset of action and poor tolerability still remain challenging in some patients.11 Currently, there is no universally accepted standard treatment regimen for DED; it is generally personalized, based on the individual prescriber’s preference, belief, or experience,13 despite the International Tear Film & Ocular Surface Society (TFOS) Dry Eye Workshop II (DEWS II) guidelines.14

Lifitegrast 5.0% is a small molecule integrin competitive antagonist that inhibits T-cell–mediated inflammation by blocking lymphocyte function-associated antigen 1/intercellular adhesion molecule-1 binding, resulting in a decreased ocular inflammatory cycle.11,15 Lifitegrast was approved for use in DED in the United States (US) and Canada in 2016 and 2018, respectively.16,17 The efficacy and safety of lifitegrast 5.0% in improving the signs and symptoms of DED is well established in clinical trials.18–22 The long-term safety of lifitegrast in patients with DED was demonstrated in SONATA (Safety Of a 5.0% coNcentrATion of lifitegrAst ophthalmic solution).22 The recently published US/Canada real-world evidence (RWE) chart review study demonstrated that the majority of patients receiving lifitegrast treatment had a considerable reduction in overall treatment burden and improvement in DED signs and symptoms 6 months after lifitegrast initiation.21

The aim of this report is to evaluate whether treatment with lifitegrast can provide sustained symptomatic relief such that patients become less reliant on the overall use and frequency of ATs. Patient data from SONATA22 and the RWE chart review study21 have been analyzed separately.

Materials and Methods

Study Design

SONATA was an Independent Review Board (IRB)-approved 1-year, Phase 3, multicenter, randomized, prospective, double-masked, placebo-controlled, parallel-arm study conducted at 22 sites in the US (identifier, NCT01636206).22 The RWE chart review study was an IRB-approved non-interventional, retrospective, longitudinal cohort study using patient charts from both the US and Canada that were obtained through a healthcare provider panel.21 The study design and eligibility criteria for each study have been published previously.21,22 Details of the IRBs of the SONATA and RWE studies are provided in .

In the RWE study, the pre-index period was defined as the 6-month period prior to initiation of lifitegrast treatment (ie, no lifitegrast therapy), while the post-index period was defined as the 12-month period following lifitegrast treatment (along with other adjunct DED therapies).21

Efficacy Outcomes

The main outcome of this study was to measure changes in the proportion of patients using ATs post-initiation of lifitegrast therapy. Examining the concurrent use/reliance on ATs reflects patients’ needs to reach for a rescue therapy to quickly alleviate any uncontrolled symptoms associated with DED. Hence, a reduction in AT use could be an indicator that the associated symptoms are more controlled resulting in a gradual decline of AT use as a rescue therapy.

Statistical Analysis

Data from both the SONATA and RWE chart review studies were analyzed using descriptive statistics and expressed as proportions with two-sided 95% confidence intervals (CIs) for categorical variables and means, standard deviations (SDs), and medians for continuous variables. Ninety-five percent CIs for categorical variables were calculated using the Clopper–Pearson method.

Results

Demographics and Other Baseline Characteristics

SONATA

While the demographic characteristics of SONATA study are summarized in Table 1, data from a total of 293 patients (lifitegrast, n=195; placebo, n=98; safety population set) from the on-therapy period were used for this analysis. The mean age (SD) of patients who used or did not use ATs was 61.3 (11.5 years) and 58.8 years (12.8 years), respectively. The majority of analyzed patients who used (n=89; 83.2%) and did not use (n=132; 71.0%) ATs were female.

Table 1

Demographic and Baseline Clinical Characteristics of SONATA and RWE Chart Review Studies

SONATA
Demographics Characteristics	Lifitegrast (n=211)	Placebo (n=111)
Age, years
Mean (±SD)	58.8 (±12.39)	61.0 (±13.18)
≥75 years, n (%)	19 (8.6)	15 (13.5)
Female, n (%)	165 (74.7)	85 (76.6)
Ethnicity, n (%)
Hispanic or Latino	33 (14.9)	17 (15.3)
Race, n (%)
White	176 (79.6)	92 (82.9)
RWE Chart Review
Demographic characteristics	Lifitegrast (N=600)
Age, years (at index date)
Mean (±SD) [95% CI]	57.1 (±12.8) [56.1, 58.1]
Age range, n (%) [95% CI]
18–34	34 (5.7) [4.0, 7.8]
35–49	129 (21.5) [18.3, 25.0]
50–64	278 (46.3) [42.3, 50.4]
65–69	70 (11.7) [9.2, 14.5]
70–74	50 (8.3) [6.2, 10.8]
75–79	25 (4.2) [2.7, 6.1]
80–84	8 (1.3) [0.6, 2.6]
≥85	6 (1.0) [0.4, 2.2]
Female, % (95% CI)	75.8 (72.2, 79.2)
Type of DED, % (95% CI)
Evaporative deficiency only	62.7 (58.7, 66.5)
Aqueous deficiency only	5.3 (3.7, 7.4)
Both evaporative and aqueous deficiency	26.7 (23.2, 30.4)
Ocular Disease/Conditions, % (95% CI)
Amblyopia	1.2 (0.5, 2.4)
Cataract	33.8 (30.1, 37.8)
Glaucoma	5.5 (3.8, 7.6)
Macular degeneration	4.0 (2.6, 5.9)
Previous ocular iInjury	2.5 (1.4, 4.1)
Strabismus	0.5 (0.1, 1.5)
Other*	4.8 (3.3, 6.9)
None	55.7 (51.6, 59.7)
Unknown	0.3 (0.0, 1.2)
Contact Lens Usage, % (95% CI)
Daily Ddisposable	12.0 (9.5, 14.9)
Weekly disposable	5.0 (3.4, 7.1)
Monthly disposable	6.7 (4.8, 9.0)
Disposable soft	2.2 (1.2, 3.7)
Extended wear	0.7 (0.2, 1.7)
Gas permeable	1.3 (0.6, 2.6)
None	73.0 (69.3, 76.5)
Unknown	0.2 (0.0, 0.9)

Notes: *Included allergic conjunctivitis, anatomically narrow angles, blepharitis, chalazion, conjunctivochalasis, corneal dystrophy, dermatochalasis, diabetic retinopathy, drusen, epiRetinal membrane, filamentary keratitis, giant papillary conjunctivitis, keratoconus, lagophthalmos, penetrating keratoplasty, posterior vitreous detachment, pseudophakia, pterygium, recurrent corneal erosion, retinal detachment, retinal hole, Stevens–Johnson syndrome, superficial punctate keratitis, and uveitis.

Abbreviations: CI, confidence interval; DED, dry eye disease; SD, standard deviation.

RWE Chart Review

Overall, 600 patients (US, n=550; Canada, n=50) from the RWE chart review study were included in this analysis. In the RWE chart review, the mean age (SD) at baseline was 57.1 years (12.8 years); the majority were female (n=455; 75.8%). Among patients who were diagnosed with DED, 160 patients (26.7%) reported both evaporative and aqueous deficiencies, while 376 patients (62.7%) and 32 (5.3%) patients, respectively, were diagnosed with evaporative and aqueous deficiency alone. Before the index day, ≥75% of subjects (n=453) were using OTC ATs. At the time of lifitegrast initiation, ~28% of patients (n=167; 27.8%) in the RWE chart review study had a history of contact lens use (daily, weekly, and monthly disposable, disposable soft, extended wear, and gas permeable) (Table 1).

During the on-therapy period of the SONATA study, 107 patients (36.5%) used ATs (lifitegrast, n=64 [59.8%]; placebo, n=43 [40.2%]) and 186 patients (63.5%) did not (lifitegrast, n=131 [70.4%]; placebo, n=55 [29.6%]). At any time during the on-therapy period, the proportion of patients who did not need ATs was always higher in the lifitegrast group compared with placebo (67.2% [n=131/195] vs 56.1% [n=55/98]) (Figure 1). A similar trend was observed during all study time-points (Figure 1).

Figure 1

Proportion of patients who did not use artificial tears in the lifitegrast and placebo groups of the SONATA study (safety population).

In the RWE chart review study, of the 281 patients with the 12-month follow-up, the majority of patients (n=238; 84.7%) remained on lifitegrast therapy at 12 months. During the post-index period, 226 patients (37.7%) were reported to be treated with lifitegrast alone, while among patients with lifitegrast plus adjunct combinations, the pre- versus post-index periods showed that there was an ~40.2% reduction in the use of OTC ATs (453 vs 271; 75.5% vs 45.2%), a 43.8% reduction in lid hygiene (313 vs 176; 52.2% vs 29.3%), and a 79.6% reduction in the use of topical corticosteroids (113 vs 23; 18.8% vs 3.8%) (Figure 2).

Figure 2

Proportion of patients with DED-related treatments during the pre- and post-index period in the RWE chart review. *Only medication reported in the medical charts are reported as a post-index combination therapy with lifitegrast.

With lifitegrast alone or in combination with other adjunct therapies (autologous serum [n=20], OTC ATs [n=453], lid hygiene techniques [n=313], oral or topical CsA [n=123], and topical corticosteroids [n=113]), there was a reduction in patient-reported symptoms over the post-index versus pre-index period, including eye dryness (5%; 95% CI: 2.9–8.0 vs 87.5%; 95% CI: 84.6–90.0), blurred vision (3.4%; 95% CI: 1.7–6.1 vs 57.7%; 95% CI: 53.6–61.7), ocular stinging or burning (2.5%; 95% CI: 1.1–4.9 vs 56.0%; 95% CI: 51.9–60.0), foreign body sensation (2.5%; 95% CI: 1.1–4.9 vs 49.8%; 95% CI: 45.8–53.9), and ocular pain (0.6%; 95% CI: 0.1–2.2 vs 12.2%; 95% CI: 9.7–15.1) (Table 2).21

Table 2

DED Symptoms Reported During the Preindex and Postindex Periods in the RWE Chart Review Study

Symptoms	Preindex (n=600)% (95% CI)	Postindex (n=320)% (95% CI)
Blurred vision	57.7 (53.6, 61.7)	3.4 (1.7, 6.1)
Eye dryness	87.5 (84.6, 90.0)	5.0 (2.9, 8.0)
Foreign body sensation	49.8 (45.8, 53.9)	2.5 (1.1, 4.9)
Ocular stinging or burning	56.0 (51.9, 60.0)	2.5 (1.1, 4.9)
Ocular pain	12.2 (9.7, 15.1)	0.6 (0.1, 2.2)

Discussion

The results from the SONATA and RWE chart review studies showed a consistent decreased use of OTC ATs as a rescue therapy following lifitegrast treatment in patients with DED. In the SONATA trial, a higher proportion of patients reported not using ATs in the lifitegrast group compared with placebo (67.2% vs 56.1%) during the 1-year period.22 In the RWE chart review study, the proportion of patients using ATs was reported to be 40.2% lower during the 12-month post-index period following lifitegrast treatment compared with the pre-index period.21

In the SONATA trial, the proportion of patients using ATs gradually decreased from Day 270–360 in those who were treated with lifitegrast; patients on placebo showed no decline. These data show that lifitegrast, apart from addressing the inflammation, also provides sustained relief of symptoms, which can help to reduce the reliance/dependence on ATs for temporary short-term symptomatic relief.

In the RWE chart review study, there was a reduction in the proportion of patients who were using lid hygiene and topical corticosteroids. Following lifitegrast treatment, the proportion of patients using lid hygiene was reduced by 43.8% compared with the pre-index period. This is important since lid hygiene has been considered the first-line therapy in patients with meibomian gland dysfunction and blepharitis.6,23 Lid hygiene is inconvenient and time-consuming,24 hence, a decline in its usage may also help reduce treatment burden in patients with DED. Moreover, there was an ~80% reduction in the use of topical corticosteroids in the post-index period compared with pre-index, reducing the risk of adverse events (AEs) from steroids.25,26

Treatment and management of DED pose a significant direct burden on healthcare and the indirect economic burden on patients and society is often ignored.27,28 A study conducted in the Singapore National Eye Center, which collected cost data from 54,052 patients, showed that lubricants alone accounted for 79.3% of the total treatment cost.27 A survey conducted in the US in 2171 respondents with DED showed that, from a societal perspective, the overall annual average burden of managing DED to US society was $55.4 billion – $11,302 per patient.28 Even though the results from the SONATA trial and RWE chart review study did not perform a cost estimation analysis, an overall reduction in the DED treatment economic burden of up to 80% can be estimated considering the proportion of patients in whom the use of ATs and other adjunct DED therapies were reduced following lifitegrast treatment. In the US, the usual price of bottled ATs (eg, Systane® Complete) is ~$15, whereas a preservative-free single-use AT (eg, Refresh Plus®) costs $23. Consider that patients with DED use bottled ATs 4 times daily, the cost per year would be $219. However, if such patients use preservative-free ATs every 2 hours, the cost increases to ~$959; use every 1 hour would further increase the cost to ~$1919 per year. Currently, the availability of socioeconomic data is limited, and the actual societal burden of DED is assumed to be much higher than estimated. Hence, consideration of costs while treating and managing patients with DED can prove to be beneficial to both the payers and society.

In this short report, the aim was to highlight whether lifitegrast treatment can provide sustained symptomatic relief in patients with DED and reduce dependency on ATs.11,12 Frequent use of ATs may indicate inadequate symptom control. For temporary relief from ocular discomfort while working in front of a screen, wearing contact lenses, or travelling, the use of ATs is convenient and more easily accessible compared with prescription therapy, and should continue to have a key role in management.5,6 However, ATs cannot be considered as the only resolutive treatment since they do not address the underlying inflammation.8,9

To date, this is the first such combined report from a randomized, Phase 3, clinical trial, SONATA and a RWE chart-review study involving ~900 patients, which evaluated the reduction of ATs in patients with DED following lifitegrast treatment. A limitation of this report is that the retrospectively collected data from patient charts can be biased based on patient reports, and the lack of statistical analysis due to initial study design and power. The RWE chart-review study from the US and Canada showed that >75% of recruited patients were using OTC ATs in the pre-index period; the numbers may be even higher considering that there might be under-reporting from either the patient or eye-care provider.

Conclusions

Findings from this short analysis suggest that following treatment with lifitegrast in patients with DED there is a gradual reduction in the use of ATs, indicating improved symptomatic relief and hence, a reduction in the dependency of ATs.